SCHEMBL15417360

SCHEMBL15417360

CC(C)c1cc(Cl)cnc1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
KDM5A P29375 1/20 0.36
ERBB2 P04626 1/20 0.33
USP8 P40818 1/20 0.32
USP7 Q93009 1/20 0.32
IDH1 O75874 4/20 0.32
MAPT P10636 1/20 0.31
MAPK1 P28482 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
PIK3CG P48736 1/20 0.31
S1PR1 P21453 2/20 0.30
S1PR3 Q99500 2/20 0.30
PIK3CD O00329 1/20 0.30
P2RX3 P56373 1/20 0.30
P2RX2 Q9UBL9 1/20 0.30
MAP4K1 Q92918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL186605 0.78 KDM4E (0.47) KDM4EALDH1A1POLBERBB2USP8
SCHEMBL15417374 0.78 JAK2 (0.36) KDM5A
SCHEMBL17574705 0.76 GABRA1 (0.45) GABRA1GABRB1MAPK1S1PR1S1PR3
SCHEMBL23482226 0.75 USP8 (0.37) KDM4EALDH1A1KDM5AERBB2USP8
SCHEMBL4586295 0.75 KDM4E (0.40) KDM4EALDH1A1POLBUSP8USP7
SCHEMBL17947393 0.74 ALDH1A1 (0.41) KDM4EALDH1A1POLBKDM5AERBB2
SCHEMBL12186129 0.74 S1PR1 (0.38) ALDH1A1POLBIDH1PIK3CGS1PR1
SCHEMBL12356952 0.74 GABRA1 (0.46) GABRA1GABRB1ALDH1A1MAPK1
SCHEMBL19958438 0.72 GABRA1 (0.45) GABRA1GABRB1MAPK1
SCHEMBL12099239 0.72 ALDH1A1 (0.41) KDM4EALDH1A1POLBUSP8USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
US-8623889-B2 Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof GENENTECH, INC. (US) 2014-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 GABRA1 1936/4885GABRB1 1849/4885KDM4E 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.